The University of Texas has sold its TEX-Core anticancer drug platform to an enterprise dedicated to developing early stage bioscience assets known as IQ Group Global. TEX-Core, an anticancer drug platform, that has the ability to develop a range of well tolerated, MRI-detectable cancer therapeutics that target drug sensitive and drug-resistant tumors.
TrialSite News follows with a breakdown of this deal, the players, and the potential via our question and answer format.
What is TEX-Core?
An anticancer drug platform that possesses the ability for developers to harness a range of well-tolerated, MRI-detectable cancer therapeutics that target drug-sensitive and drug resistant tumors. The CEO of the IQ Group Global called TEX-Core “A landmark development in oncology that will significantly improve the efficacy of platinum-based cancer therapeutics.”
What will be the first cancer therapeutic IQ Group Global will develop?
The first cancer therapeutic to be commercialized from the platform is OxaliTEX, a novel chemical entity (WO 2015/191797) that targets only solid tumor cells, activates within the tumor and overcomes drug-resistance mechanisms within minimal side effects.
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).